Replimune (REPL) Total Current Liabilities (2018 - 2026)
Replimune (REPL) reported Total Current Liabilities of $58.2 million for Q1 2026, down 6.63% on a YoY basis from $62.4 million in Q1 2025, and up 16.25% sequentially from $50.1 million in Q4 2025.
Replimune (REPL) Total Current Liabilities (2018 - 2026) Analysis & Trends
Replimune (REPL) has 9 years of Total Current Liabilities data on file, last reported at $58.2 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities fell 6.63% year-over-year to $58.2 million; the trailing twelve-month figure through Mar 2026 stood at $58.2 million (down 6.63% YoY), and the FY2026 full-year result was $58.2 million, down 6.63% from the prior year.
- Total Current Liabilities improved to $58.2 million in Q1 2026, from $50.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $62.4 million in Q1 2025 to a low of $20.3 million in Q2 2022.
- A 5-year average of $40.4 million and a median of $39.8 million in 2023 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities soared 69.23% in 2023 and retreated 6.63% in 2026, its largest moves.
- Tracing REPL's Total Current Liabilities over 5 years: stood at $26.5 million in 2022, then soared by 46.05% to $38.6 million in 2023, then rose by 23.91% to $47.9 million in 2024, then advanced by 4.59% to $50.1 million in 2025, then climbed by 16.25% to $58.2 million in 2026.
- Business Quant data shows REPL's Total Current Liabilities at $58.2 million in Q1 2026, $50.1 million in Q4 2025, and $52.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | 58.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.23 Mn |
| Dec 31, 2025 | 50.09 Mn |
| Sep 30, 2025 | 52.90 Mn |
| Jun 30, 2025 | 59.56 Mn |
| Mar 31, 2025 | 62.36 Mn |
| Dec 31, 2024 | 47.89 Mn |
| Sep 30, 2024 | 43.79 Mn |
| Jun 30, 2024 | 35.68 Mn |
| Mar 31, 2024 | 40.44 Mn |
| Dec 31, 2023 | 38.65 Mn |
| Sep 30, 2023 | 39.83 Mn |
| Jun 30, 2023 | 32.24 Mn |
| Mar 31, 2023 | 33.83 Mn |
| Dec 31, 2022 | 26.46 Mn |
| Sep 30, 2022 | 23.54 Mn |
| Jun 30, 2022 | 20.31 Mn |
| Mar 31, 2022 | 20.76 Mn |
| Dec 31, 2021 | 18.29 Mn |
| Sep 30, 2021 | 16.64 Mn |
| Jun 30, 2021 | 15.05 Mn |